Product Name: Acetylated Lysine
Product Number: AB-NN135-1
| Size: | 25 µg | Price: | 89.00 | |
| $US |
Target Full Name: Acetylated Lysine in proteins
Target Alias: Acetyl lysine
Product Type Specific: Acetylated lysine pan-specific antibody
Antibody Code: NN135-1
Antibody Target Type: Pan-specific
Antibody Type: Polyclonal
Antibody Host Species: Rabbit
Antibody Ig Isotype Clone: N/A
Antibody Immunogen Source: Acetylated KLH Conjugated
Production Method: Affinity purified
Antibody Modification: Unconjugated. Contact KInexus if you are interest in having the antibody biotinylated or coupled with fluorescent dyes.
Target Alias: Acetyl lysine
Product Type Specific: Acetylated lysine pan-specific antibody
Antibody Code: NN135-1
Antibody Target Type: Pan-specific
Antibody Type: Polyclonal
Antibody Host Species: Rabbit
Antibody Ig Isotype Clone: N/A
Antibody Immunogen Source: Acetylated KLH Conjugated
Production Method: Affinity purified
Antibody Modification: Unconjugated. Contact KInexus if you are interest in having the antibody biotinylated or coupled with fluorescent dyes.
Antibody Concentration: 1 mg/ml
Storage Buffer: Phosphate buffered saline, 50% glycerol, 0.09% sodium azide
Storage Conditions: For long term storage, keep frozen at -40°C or lower. Stock solution can be kept at +4°C for more than 3 months. Avoid repeated freeze-thaw cycles.
Product Use: Western blotting | ICC/Immunofluorescence | Immunoprecipitation | ELISA
Antibody Dilution Recommended: WB (1:250), ICC/IF (1:100); optimal dilutions for assays should be determined by the user.
Antibody Potency: Medium-high potency. Detects a proteins containing acetylated lysine residues.
Antibody Species Reactivity: Species Independent
Storage Buffer: Phosphate buffered saline, 50% glycerol, 0.09% sodium azide
Storage Conditions: For long term storage, keep frozen at -40°C or lower. Stock solution can be kept at +4°C for more than 3 months. Avoid repeated freeze-thaw cycles.
Product Use: Western blotting | ICC/Immunofluorescence | Immunoprecipitation | ELISA
Antibody Dilution Recommended: WB (1:250), ICC/IF (1:100); optimal dilutions for assays should be determined by the user.
Antibody Potency: Medium-high potency. Detects a proteins containing acetylated lysine residues.
Antibody Species Reactivity: Species Independent
Antibody Positive Control: A 1/250 dilution of SPC-155 was sufficient to detect the acetylated histone from TSA treated mouse spleen cell in western blot analysis.
Antibody Specificity: Very high
Antibody Cross Reactivity: No reaction to non-acetylated proteins.
Related Product 1: Acetylated lysine pan-specific antibody (Cat. No.: AB-NN135-2)
Antibody Specificity: Very high
Antibody Cross Reactivity: No reaction to non-acetylated proteins.
Related Product 1: Acetylated lysine pan-specific antibody (Cat. No.: AB-NN135-2)
Scientific Background: Post-translational modifications of proteins play critical roles in the regulation and function of many known biological processes. Proteins can be post-translationally modified in many different ways, and a common post-transcriptional modification of Lysine involves acetylation (1). The conserved amino-terminal domains of the four core histones (H2A, H2B, H3 and H4) contain lysines that are acetylated by histone acetyltransferases (HATs) and deacetylated by histone deacetylases (HDACs) (2). Protein posttranslational reversible lysine Nε-acetylation and deacetylation have been recognized as an emerging intracellular signaling mechanism that plays critical roles in regulating gene transcription, cell-cycle progression, apoptosis, DNA repair, and cytoskeletal organization (3). The regulation of protein acetylation status is impaired in the pathologies of cancer and polyglutamine diseases (4), and HDACs have become promising targets for anti-cancer drugs currently in development (5).
References
[1] Yang X.J. (2005) Oncogene. 24:1653-1662.
[2] Hassig C.A. and Schreiber S.L. (1997) Curr. Opin. Chem. Biol. 1(3): 300-308.
[3] Yang X.J. (2004) Bioessays 26:1076-1087.
[4] Hughes R.E. (2002) Curr. Biol. 12: R141-R143.
[5] Vigushin D.M. and Coombes R.C. (2004) Curr. Cancer Drug Targets 4: 205-218.
[6] Chan H.M. et al. (2001) Nat. Cell Biol. 3: 667-674.
[7] Martinez-Balbas M.A. et al. (2000) EMBO J. 19: 662-671.
[1] Yang X.J. (2005) Oncogene. 24:1653-1662.
[2] Hassig C.A. and Schreiber S.L. (1997) Curr. Opin. Chem. Biol. 1(3): 300-308.
[3] Yang X.J. (2004) Bioessays 26:1076-1087.
[4] Hughes R.E. (2002) Curr. Biol. 12: R141-R143.
[5] Vigushin D.M. and Coombes R.C. (2004) Curr. Cancer Drug Targets 4: 205-218.
[6] Chan H.M. et al. (2001) Nat. Cell Biol. 3: 667-674.
[7] Martinez-Balbas M.A. et al. (2000) EMBO J. 19: 662-671.
© Kinexus Bioinformatics Corporation 2017